Pharma BD Deal Intelligence
SK Biopharmaceuticals and Insilico Medicine formed an AI-powered drug discovery collaboration, announced at the BIO 2026 International Convention, to discover novel candidates for neuroimmune CNS disorders using Insilico's generative AI platform. Insilico receives ~$18M in near-term payments and is eligible for up to $2.5 billion in milestones plus single-digit royalties; SK Biopharmaceuticals leads subsequent development and commercialization. It is Insilico's largest APAC partnership by potential value.